September 30, 2025 — Gilead’s Epclusa (sofosbuvir/velpatasvir, 400mg/100mg) continues to reshape hepatitis C management worldwide. As the first and only all-oral, pan-genotypi...
With the rapid development of precision medicine, targeted drugs have become a key approach in cancer treatment. Unlike traditional chemotherapy, targeted therapy “hits” specific...